Neurofilament light chain as a biomarker of meningoencephalitis of unknown etiology in dogs

Taesik Yun1 | Yoonhoi Koo1 | Yeon Chae1 | Dohee Lee1 | Hakhyun Kim1 | Soochong Kim2 | Dongwoo Chang3 | Ki-Jeong Na4 | Mhan-Pyo Yang1 | Byeong-Teck Kang1

1Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
2Laboratory of Veterinary Pathology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
3Section of Veterinary Medical Imaging, Veterinary Teaching Hospital, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
4Laboratory of Veterinary Laboratory Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea

Correspondence
Byeong-Teck Kang, Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea.
Email: kangbt@chungbuk.ac.kr

Funding information
Ministry of Science and ICT, Grant/Award Number: 2021R1A2C1012058; Ministry of Education, Grant/Award Number: 2020R1A6A3A13077423

Abstract
Background: Neurofilament light chain (NfL) is a neuron-specific cytoskeletal protein expressed in axons. Damaged axons of the central nervous system release NfLs into the cerebrospinal fluid (CSF) and the blood. In humans with neurologic diseases, NfL is used as a biomarker.

Objectives: To identify the potential of NfL as a supportive tool for the diagnosis, prognosis, and monitoring of meningoencephalitis of unknown etiology (MUE) in dogs.

Animals: Twenty-six client-owned healthy dogs, 10 normal Beagle dogs, and 38 client-owned MUE dogs.

Methods: Cohort study. The concentrations of NfL in serum and CSF were measured using single-molecule array technology.

Results: Median NfL concentration was significantly higher in MUE dogs (serum, 125 pg/mL; CSF, 14 700 pg/mL) than in healthy dogs (serum, 11.8 pg/mL, P < .0001; CSF, 1410 pg/mL, P = .0002). The areas under the receiver operating characteristic curves of serum and CSF NfL concentrations were 0.99 and 0.95, respectively. The cut-off values were 41.5 pg/mL (serum) and 4005 pg/mL (CSF) for differentiating between healthy and MUE dogs, with sensitivities of 89.19% and 90%, respectively, and specificities of 96.97% and 100%, respectively. The NfL concentration showed a significant decrease (pretreatment, 122 pg/mL; posttreatment, 36.6 pg/mL; P = .02) in the good treatment-response group and a significant increase (pretreatment, 292.5 pg/mL; posttreatment, 1880 pg/mL, P = .03) in the poor treatment-response group.

Conclusions and Clinical importance: Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.

Keywords
Cerebrospinal fluid (CSF), MUE, MUO, NfL, serum, single-molecule array (Simoa)
1 | INTRODUCTION

Neurofilaments (Nfs) are neuron-specific cytoskeletal proteins that are highly expressed in axons. They play a pivotal role in supporting and maintaining axonal structure, size, shape, and caliber. On the basis of sodium dodecyl sulfate polyacrylamide gel electrophoresis, Nfs were found to consist of 3 subunits: Nf-light (NfL; 68-86 kDa), Nf-medium (145-160 kDa), and Nf-heavy (200-220 kDa) chains. When axonal damages in the central nervous system (CNS) occur because of inflammatory, neurodegenerative, vascular, and traumatic disorders, Nfs are released into the cerebrospinal fluid (CSF) and subsequently into the bloodstream. Recently, serum or plasma and CSF NfL concentrations have been shown to reflect neuroaxonal damage and to be potential prognostic biomarkers for disease activity, progression, and treatment response in human patients with neurological diseases including human immunodeficiency virus-associated dementia, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, multiple sclerosis (MS), traumatic brain injury, normal pressure hydrocephalus, Alzheimer’s disease, and Parkinson’s disease.

An important feature of a biomarker is the feasibility of objective evaluation and measurement as an indicator of normal physiologic and pathogenic processes or therapeutic responses. Many studies in humans with CNS disorders have investigated the potential role of biomarkers in diagnosis, evaluation of prognosis, and monitoring of treatment response. However, studies on biomarkers associated with CNS diseases in veterinary medicine are rare. Biomarkers suitable for incorporation in routine clinical practice must be easy to detect (in serum or plasma) and cost-effective. Therefore, NfL could be a potential CNS biomarker in veterinary medicine because its concentration can be easily measured in serum or plasma as well as in CSF.

To the best of our knowledge, no reports describe NfL as a biomarker of meningoencephalitis of unknown etiology (MUE) in dogs. We hypothesized that serum and CSF NfL concentrations would increase in dogs with MUE. Based on this hypothesis, we set out to establish the utility of serum and CSF NfL concentrations as accessible biomarkers for the diagnosis of MUE as well as for monitoring of disease severity and progression and treatment response.

2 | MATERIALS AND METHODS

2.1 | Animals

This retrospective cohort study included 26 client-owned healthy dogs, 10 normal Beagle dogs, and 38 client-owned dogs with MUE. Client-owned healthy and MUE dogs that visited our institution from January 2014 to October 2020 were evaluated. The healthy control group consisted of normal Beagle dogs and dogs that were presented for health examination and were considered clinically healthy. Meningoencephalitis of unknown etiology is clinically diagnosed based on the medical history, signalment, findings on neurologic examination, magnetic resonance imaging (MRI) findings, CSF analysis, exclusion of infectious diseases, histopathological confirmation, or some combination of these. In the absence of histopathological findings, a presumptive diagnosis of MUE was made if all of the following criteria were satisfied: (a) dogs were >6 months of age, (b) single or multifocal neurologic signs were observed, (c) hyperintense lesions were observed on T2-weighted and fluid-attenuated inversion recovery images, (d) CSF abnormalities (increased protein concentration and pleocytosis with >50% mononuclear cells [monocytes and lymphocytes]) were noted, and (e) the presence of infectious diseases was ruled out.

2.2 | Treatment protocol

Dogs with MUE were treated using a combination of prednisolone (1.5 mg/kg, PO, q12h; Solondo, Yuhan, Seoul, South Korea) and other immunomodulatory agents such as mycophenolate mofetil (20 mg/kg, PO, q12h; Roche, Basel, Switzerland) and cytosine arabinoside (50 mg/m², SC, q12h for 48 hours, repeated every 3 weeks; Cytosar-U, Pfizer, New York, NY). Prednisolone generally was tapered using the following protocol: 1.5 mg/kg q12h for 3 weeks; 1.0 mg/kg q12h for 6 weeks; 0.5 mg/kg q12h for 3 weeks; 0.5 mg/kg q24h for 3 weeks; and 0.5 mg/kg q48h for maintenance.

2.3 | Serum and CSF collection

Blood samples were collected into serum-separating tubes from the jugular or a peripheral vein at the first visit and 6 months after the first treatment or before death or euthanasia. Serum was separated by centrifugation (2000g, 10 minutes) at room temperature and stored at −80°C within 2 hours of collection until further use. The CSF was obtained from the cerebellomedullary cistern using a 22-gauge spinal needle at the first visit. Whereas CSF of dogs with MUE was collected under general anesthesia administered for MRI, control CSF from normal Beagle dogs was obtained after inducing short-term anesthesia using alfaxalone (3 mg/kg, IV; Alfaxan, Jurox Pty Ltd, Rutherford, NSW, Australia). The CSF was collected in a plain tube without EDTA and stored at −80°C until further use.

2.4 | Measurement of NfL concentration

Serum and CSF concentrations of NfL were determined using single-molecule array (Simoa) technology (Quanterix, Billerica, Massachusetts). The assay was performed using a Simoa HD-1 Analyzer (Quanterix, Billerica, Massachusetts) with the NfL assay kit designed for humans using an anti-NfL monoclonal antibody (UmanDiagnostics, Umeå, Sweden). The NfL concentrations were measured in duplicate according to the manufacturer’s instructions. Two control samples (high and low concentration) provided with the kit were analyzed in duplicate in each run for quality control. When the concentration of control samples was within the given range, the assay precision was considered to be satisfactory. For quality control samples with
concentrations of 5.21 and 192 pg/mL, the intra-assay coefficients of variation were 4.8% and 0.3%, respectively; the interassay coefficients of variation were <15%.

2.5. Grouping and data analysis

The concentrations of NfL in both serum and CSF were measured at the first visit and compared between the healthy and MUE dogs to evaluate the differences at the onset of initial clinical signs. For serum NfL analysis, 26 client-owned and 7 normal Beagle dogs were included in the healthy control group (n = 33), and 37 client-owned dogs were included in the MUE group (n = 37). For CSF NfL analysis, 10 normal Beagle dogs and 10 client-owned dogs were included in the healthy control group (n = 10) and the MUE group (n = 10), respectively.

A receiver operator characteristic (ROC) curve was used to evaluate the cut-off value with sensitivity and specificity for the diagnosis of MUE.

Magnetic resonance imaging was performed using a 0.3-Tesla unit (Airis II, Hitachi, Japan) or 1.5-Tesla unit (Signa Creator, GE Healthcare, Milwaukee, Wisconsin). The T1-weighted (pre- and post-contrast), T2-weighted, and fluid-attenuated inversion recovery images were acquired in transverse, sagittal, and dorsal planes. To identify the correlation between lesion volume and NfL, the ratio of lesion volume to the entire brain volume was obtained. The volumes of the lesion and entire brain, which were defined using transverse fluid-attenuated inversion recovery images, were measured using a commercial image viewer (OsiriX MD v10.0, Pixmeo Sarl, Geneva, Switzerland) by adding all of the cross-sectional areas calculated on each transverse image. The ratio of the lesion volume was generated by dividing the lesional volume by the volume of the entire brain. For a more objective evaluation of the effect of lesion volume, dogs with spinal lesions were excluded because of the absence of complete MRI findings of the spinal cord. Thus, the serum group consisted of 32 dogs, and the CSF group consisted of 7 dogs.

To examine the effect of seizures on NfL, the MUE dogs were divided into 2 subgroups depending on the presence or absence of seizures: the seizure group (22 MUE dogs) and the nonseizure group (15 MUE dogs). The concentrations of NfL at the first visit in both the serum and CSF were measured and compared between the seizure and nonseizure groups to evaluate the utility of NfL as a biomarker for seizure in dogs with MUE.

Posttreatment or predeath (including pre-euthanasia) serum NfL concentrations were compared to those at the first visit to evaluate the utility of NfL as a biomarker for treatment response. For this analysis, the dogs with MUE were divided into 2 subgroups depending on the frequency and recurrence of neurologic signs. According to the therapeutic response, the good treatment-response group (n = 7) included dogs with no neurologic signs until approximately 6 months posttreatment, and the poor treatment-response group (n = 6) included the dogs that died or were euthanized because of periodic neurologic signs.

2.6. Statistical analysis

Statistical analyses were performed using the Prism 9 software (Graphpad Software Inc, San Diego, California). The results are expressed as medians and interquartile ranges. A 2-sided P-value <.05 was considered statistically significant. The assessment of normal distribution was performed using the Shapiro-Wilk test, and a normal distribution was not identified. Therefore, nonparametric tests were used for the assessments. To compare the differences in the serum and CSF NfL concentrations between the healthy and MUE dogs and between the seizure and nonseizure groups, the Mann-Whitney U test was used. To determine the optimal cut-off value of serum and CSF NfL concentrations for differentiating between healthy dogs and dogs with MUE, the area under the ROC curve (AUC) was measured. The correlation between the ratio of lesion volume and NfL concentration was evaluated using Spearman’s rank test. The Wilcoxon signed rank sum test was used to evaluate the change in the NfL concentration from before and after MUE treatment to identify treatment response.

3. RESULTS

3.1. Study population

Seventy-four dogs (healthy group, 36 dogs; MUE group, 38 dogs) were included in the study. The healthy group consisted of 10 Beagles, 1 Labrador Retriever, 4 mixed-breed dogs, 6 Toy or Miniature Poodles, 4 Bichon Frise, 1 Shiba Inu, 2 Welsh Corgis, 1 Spitz, 1 Yorkshire terrier, 2 Maltese, 2 Pomeranians, and 2 Miniature Schnauzers. The MUE group consisted of 21 Maltese, 2 Shih Tzus, 3 Yorkshire Terriers, 6 Chihuahuas, 7 Pomeranians, 1 Miniature Pinscher, 1 Toy

| TABLE 1 | Characteristics of healthy dogs and dogs with MUE |
|----------|--------------------------------------------------|
|          | Healthy dogs (n = 36)                          | MUE dogs (n = 38) |
| Age (years) | 3 (2-4.5)                                      | 5.3 (3-7.4)    |
| Body weight (kg) | 6.5 (4.5-8.1)                                | 2.8 (2.2-4.2) |
| Sex (number)  | Male 15 (41.7%)                                | 19 (50%)       |
|             | Female 21 (58.3%)                              | 19 (50%)       |
| Seizure (number) | Present –                                        | 22 (59.5%)     |
|              | Interval from last seizure to sampling          | 0 day (n = 17); 1 day (n = 1); 2 days (n = 1); 3 days (n = 1); 4 days (n = 1); no data (n = 1) |
|              | Absent –                                        | 15 (40.5%)     |

Notes: The results are expressed as medians and interquartile ranges. Abbreviation: MUE, meningoencephalitis of unknown etiology.
Poodle, 1 Japanese Chin, and 1 mixed-breed dog. Other demographic characteristics of the study dogs are presented in Table 1.

3.2 | NfL concentrations in healthy dogs and dogs with MUE

Concentrations of NfL in MUE dogs (serum \( n = 37 \): 125 [76.7-554] pg/mL; CSF \( n = 10 \): 14 700 [5405-16 050] pg/mL) were significantly higher than those in healthy dogs (serum \( n = 33 \): 11.8 [8.7-16.9] pg/mL, \( P < .0001 \); CSF \( n = 10 \): 1410 [962-2388] pg/mL, \( P = .0002 \), Figure 1).

3.3 | AUC of NfL concentration in dogs with MUE

The AUCs of the serum and CSF NfL concentrations were 0.99 (95% confidence interval [CI], 0.9676-1.000) and 0.95 (95% CI, 0.8477-1.000), respectively (Figure 2). The corresponding optimal cut-off values to distinguish between healthy dogs and dogs with MUE are presented in Table 1.
FIGURE 3  Correlations between theNFL concentrations and the ratio of lesion volume to the entire brain volume in dogs with MUE (serum: A, n = 32, P = .14, r = 0.27; CSF: B, n = 7, P = .3, r = 0.46). Dotted lines represent the 95% confidence intervals. Spearman's rank test. CSF, cerebrospinal fluid; MUE, meningoencephalitis of unknown etiology; NFL, neurofilament light chain

FIGURE 4  Serum (A) and CSF (B) NFL concentrations in dogs with MUE depending on the presence of seizure. A, The concentration of serum NFL in MUE dogs with seizure (n = 22) was relatively higher than that in MUE dogs without seizure (n = 15); however, there was no significant difference. B, The concentration of CSF NFL in MUE dogs with seizure (n = 6) was relatively higher than that in MUE dogs without seizure (n = 4); however, there was no significant difference. The horizontal bars show the medians and interquartile ranges from the first to the third quartile. Mann-Whitney U test. CSF, cerebrospinal fluid; MUE, meningoencephalitis of unknown etiology; NFL, neurofilament light chain

FIGURE 5  Alterations in serum NFL concentration posttreatment in dogs with MUE according to therapeutic response. A, There was a significant decrease in NFL concentration in the good treatment-response group (n = 7) at 6 months after commencement of treatment. B, There was a significant increase in NFL concentration in the poor treatment-response group (n = 6) just before death or euthanasia. Wilcoxon-signed rank sum test. *P < .05. MUE, meningoencephalitis of unknown etiology; NFL, neurofilament light chain
were 41.5 pg/mL and 4005 pg/mL; sensitivity and specificity were 89.19% (95% CI, 75.29-95.71%) and 96.97% (95% CI, 84.68-99.84%), respectively, for the former and 90% (95% CI, 59.58-99.49%) and 100% (95% CI, 72.25-100.0%), respectively, for the latter.

3.4 | Correlation between NFL concentration and the ratio of lesion volume in dogs with MUE

Correlations of the serum and CSF NFL concentrations with the ratio of lesion volume were measured to identify the effect of lesional volume on NFL concentrations. The ratios of lesion volume in the serum and CSF groups were 0.07 (0.019-0.118) and 0.038 (0.015-0.112), respectively. There was no correlation between the ratio of lesion volume and NFL concentration in either serum (P = .14, r = 0.27) or CSF (P = .3, r = 0.46) group (Figure 3).

3.5 | Comparison of NFL concentration between MUE dogs with and without seizures

The concentrations of NFL in MUE dogs with seizures (serum [n = 22]: 167.5 [87.4-940.3] pg/mL; CSF [n = 6]: 15 150 [7477.5-16 050] pg/mL) were relatively higher than concentrations in MUE dogs without seizures (serum [n = 15]: 122 [74.9-204.5] pg/mL; CSF [n = 4]: 10 420 [5695-29 137.5] pg/mL), but no significant differences were identified (Figure 4).

3.6 | Treatment response

A significant decrease (pretreatment, 122 [97-922] pg/mL; posttreatment, 36.6 [21.4-49.7] pg/mL; P = .02) in NFL concentration was observed in the good treatment-response group (n = 7) at 6 months after commencement of treatment (Figure 5A). A significant increase (pretreatment, 292.5 [143.3-512.6] pg/mL; posttreatment, 1880 [998-2795] pg/mL; P = .03) in NFL concentration was observed in the poor treatment-response group (n = 6) just before death or euthanasia (Figure 5B). The median time interval between the first and last sampling of the poor treatment-response group was 46 days (range, 11-1021 days).

4 | DISCUSSION

Our study determined that serum and CSF NFL concentrations were significantly higher in dogs with MUE than in healthy dogs. Moreover, the concentrations of serum NFL decreased significantly 6 months after commencement of treatment in the good treatment-response group, and the concentration of serum NFL increased significantly just before death or euthanasia in the poor treatment-response group. Therefore, the concentration of NFL plays a supportive role in the diagnosis and evaluation of treatment response in dogs with MUE.

The NFs are major structural proteins that are particularly abundant in myelinated axons. Because of neuroaxonal injuries associated with neurodegeneration or inflammation, NFs are released into the CSF and peripheral blood. The concentration of NFL is increased in peripheral blood and CSF in various neurologic disorders in humans. In a meta-analysis on MS, 1665 patients (mean serum NFL, 23.06 pg/mL; mean CSF NFL, 1207 pg/mL) showed significantly higher NFL concentrations than 986 healthy people (mean serum NFL, 13.1 pg/mL; mean CSF NFL, 187.5 pg/mL). Our findings are consistent with the results of this meta-analysis on MS. Neurofilament light chain is related to the progression of brain damage, ongoing disease activity, and clinical signs including cognitive impairment, which shows that the increase of NFL in neurologic diseases indicates ongoing axonal injury. Furthermore, the concentration of NFL could provide more information on ongoing neuroaxonal injury in focal T2 lesions and diffuse normal-appearing white matter lesions that are not accurately shown by conventional MRI. Therefore, as a diagnostic biomarker, NFL, along with signalment, clinical signs, and MRI findings, improves the sensitivity and specificity of diagnosis.

Monitoring neuroaxonal damage remains an important challenge in the early diagnosis of MS. Numerous candidate diagnostic biomarkers for MS have been proposed. Among them, NFL is a potential diagnostic biomarker that is sensitive and specific to neuroaxonal injury in patients with MS and has a potential role to detect neuroaxonal damage in early MS. Cut-off values of serum and CSF NFL concentrations to distinguish patients with MS from healthy individuals were 18.2 and 900 pg/mL, respectively, and AUCs (serum: 0.663; CSF: 0.774), sensitivities (serum: 45%; CSF: 67%), and specificities (serum: 80%; CSF: 75%) were moderate. However, in our study, superior AUCs (serum: 0.99; CSF: 0.95), sensitivities (serum: 89.19%; CSF: 90%), and specificities (serum: 96.67%; CSF: 100%) were observed. Therefore, because it is also important to diagnose MUE in the early phase before the occurrence of irreversible necrotic lesions, the NFL concentration could be a useful diagnostic biomarker for MUE screening in dogs with neurologic signs.

Increased NFL concentrations in the blood and CSF of patients with MS are associated with lesion volume, brain atrophy (volume loss), and new or enlarging lesions. Moreover, patients with contrast-enhancing lesions (62.5 pg/mL) had higher serum NFL concentrations than patients without gadolinium-enhancing lesions (29.6 pg/mL). These observations indicate that patients with MS and increased NFL concentrations are at a higher risk of deterioration of brain atrophy (volume loss) and worsening of Expanded Disability Status Scale score in the long term. However, to date, none of the previous studies have investigated the correlation between lesion volume and biomarkers of MUE, including cytokines. Therefore, in our study, the ratio of lesion volume was determined to evaluate the correlation between lesion volume and NFL in MUE but no correlation was observed. The potential reason for this lack of correlation is that neuroaxonal damage probably is affected by the severity or activity of the lesion, and not the volume of the lesion.

The NFs also are known to be associated with epilepsy, but their relationship with seizures has not been systematically studied. One study suggested that NF heavy chain concentrations were significantly higher in patients with status epilepticus and repetitive generalized
tonic-clonic seizures without intracranial structural disease than in healthy controls. In our study, although the concentrations of serum and CSF NFL in the seizure group were relatively higher than those in the nonseizure group, no significant difference was found between dogs with and without seizures. A potential reason for this result includes that neuronal injury associated with structural disease overwhelms the damage caused by the seizure itself. Furthermore, the type, duration, and frequency of seizures before sampling as well as the interval from the last seizure to the time of sampling also may have effects on the NFL concentrations.

The measurement of NFL concentrations in serum and CSF has been suggested for monitoring the response to drugs intended to decrease axonal injury. Regardless of the type of disease-modifying treatment, many studies have found an inverse correlation between NFL concentrations and treatment. The concentration of NFL in patients with MS who were undergoing treatment was lower than that in patients who were not undergoing treatment. Likewise, in our study on MUE, the concentration of NFL significantly decreased in dogs showing good treatment response at 6 months after commencement of treatment. This decrease occurred possibly because the treatment helps prevent brain damage and shows the role of NFL as a biomarker of neuroaxonal injury. In the poor treatment-response group, the concentration of NFL was significantly higher than the baseline NFL concentration, showing that an NFL increase despite treatment could reflect an inappropriate treatment response. Therefore, in combination with clinical and imaging monitoring, monitoring of NFL concentration could provide information on the therapeutic response, facilitating treatment decisions.

During the past decades, biomarkers have been widely studied in medicine. The term biomarker refers to a quantifiable indicator that is measured as a variable of normal physiologic, pathogenic, or treatment responses to an intervention. Therefore, biomarkers should be used for prediction (risk of developing a disease or establishing prognosis), diagnosis (or screening), and monitoring (disease activity and treatment response) for specific diseases. Numerous candidates for various diseases have been studied, but only a few biomarkers have been thoroughly validated and are used clinically, and it is very difficult for biomarker candidates to be considered for clinical practice. In our study, although the potential role of NFL as a biomarker in MUE was identified, the clinical use of NFL as a biomarker in MUE includes many challenges. First, in choosing biomarkers, the feasibility in the clinical environment where the biomarker will be used always should be taken into account. After that, a biomarker could be used in clinical practice once it has analytical validation, such as sensitivity, accuracy, reproducibility, and practicality, and finally if it shows clinical utility.

Because the antemortem histopathological diagnosis of MUE is challenging to obtain, it has been diagnosed based on clinical signs, MRI findings, and CSF results compatible with noninfectious inflammation. Magnetic resonance imaging is sensitive (94%) and specific (95.5%) for detecting and classifying intracranial neoplasic and inflammatory lesions in dogs. However, 7% (2/25) and 14% (5/36) of dogs with MUE had normal findings on T2-weighted MRI and computed tomography images, respectively. Additionally, CSF cytology was also within normal limits in 16.7% (37/222) of dogs with MUE. Therefore, an increase in NFL concentration, which reflects neuroaxonal damage, can support a diagnosis of MUE if observed on MRI and CSF in dogs with neurologic signs.

Information on prognostic factors for MUE is limited. However, early detection of progression and therapeutic decision making may be important in the management of the disease and survival time. Although the acquisition of serial MRI is the best option for identifying the progression of MUE, it is not practical owing to the risk of anesthesia and the costs involved. In our study, the alterations in NFL concentrations were significant in the good and poor treatment-response groups. Therefore, NFL could be used with neurologic examination to evaluate the treatment response and to individualize therapeutic interventions.

Our study had some limitations. First, sample size was too small to generalize the relationship between MUE and NFL. Therefore, additional studies with a larger number of samples (especially, the CSF group and treatment group) are needed for an accurate evaluation of the relationship between MUE and NFL. Second, the healthy dogs were younger than the MUE dogs. The mean plasma concentration of NFL is proportional to normal aging, showing an age-dependent increase in healthy dogs: puppy/junior, 4.55 ± 1.70 pg/mL; adult/mature, 13.51 ± 6.80 pg/mL; and, senior/geriatric, 47.1 ± 12.68 pg/mL. Therefore, additional studies need to be performed using healthy and MUE dogs of similar ages. Third, the relationship between NFL and gadolinium-enhancing lesions was not investigated. The NFL concentration is known to be associated with the gadolinium-enhancing lesions. However, because it was difficult to count the number of contrast-enhancing lesions and to identify the margins of lesions in low-resolution images in our study, we did not compare the correlation between the number and volume of contrast-enhancing lesion and NFL concentration.

In conclusion, our study shows that NFL is a very promising biomarker for neuroaxonal injury in MUE. Our results suggest that NFL has a potential role in the diagnosis and evaluation of therapeutic effects, but it does not correlate with the volume of the lesion and the presence of seizures. In the future, additional prospective investigations may identify other potential roles of NFL.

ACKNOWLEDGMENT
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1A2C1012058) and the Ministry of Education (2020R1A6A3A13077423).

CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.

OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION
Approved by the IACUC (CBNUA-1466-20-01) of the Laboratory Animal Research Center of Chungbuk National University.

HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.

ORCID
Taeik Yun https://orcid.org/0000-0003-1372-4430
Yoonhoo Koo https://orcid.org/0000-0002-3810-4193
Yeon Chae https://orcid.org/0000-0002-9816-6900
Dohee Lee https://orcid.org/0000-0001-7162-9592
Hakhyun Kim https://orcid.org/0000-0002-8882-2329
Soohong Kim https://orcid.org/0000-0002-6739-9787
Dongwoo Chang https://orcid.org/0000-0002-7721-773X
Ki-Jeong Na https://orcid.org/0000-0001-6076-3147
Mhan-Pyo Yang https://orcid.org/0000-0002-8043-0152
Byeong-Teck Kang https://orcid.org/0000-0002-4471-4342

REFERENCES
1. Khall M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neuro. 2018;14:577-589.
2. Petzold A. Neurofilament phosphoproteins: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233:183-198.
3. Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuroen. 2016;91:1-3.
4. Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870-881.
5. Andersson A, Covacu R, Sunnemark D, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 2008;84:1248-1255.
6. Kuhle J, Kropschoder H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92:e1007-e1015.
7. Mellerård J, Edström M, Vrethem M, et al. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scier. 2010;16:208-217.
8. Michael BD, Griffiths MJ, Granerod J, et al. Characteristic cytokine and chemokine profiles in encephalitis of infectious, immune-mediated, and unknown Aetiology. PLoS One. 2016;11:e0146288.
9. Panek WK, Gruen ME, Murdoch DM, et al. Plasma neurofilament light chain as a translational biomarker of aging and neurodegeneration in dogs. Mol Neurobiol. 2020;57:3143-3149.
10. Granger N, Smith PM, Jeffery ND. Clinical findings and treatment of non-infectious meningoencephalomyelitis in dogs: a systematic review of 457 published cases from 1962 to 2008. Vet J. 2010;184:290-297.
11. Benedet AL, Ashton NJ, Pascalo TA, et al. Plasma neurofilament light associates with Alzheimer’s disease metabolic decline in amyloid-positive individuals. Alzheimers Dement (Amst). 2019;11:679-689.
12. Olby NJ, Lim JH, Wagner N, et al. Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion. J Vet Intern Med. 2019;33:726-734.
13. Cai L, Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatr Dis Treat. 2018;14:2241-2254.
14. Kuhle J, Nourbaksh B, Grant D, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017;88:826-831.
15. Saraste M, Bezukladova S, Matlaileni M, et al. High serum neurofilament associates with diffuse white matter damage in MS. Neuroimmunol Neuroinflamm. 2020;8:e926.
16. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13:113-126.
17. Burman J, Zetterberg H, Fransson M, et al. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand. 2014;130:81-89.
18. Novakova L, Zetterberg H, Sundström P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89:2230-2237.
19. Viliar LM, Picón, Costa F, Fossard L, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neuro. 2015;22:1169-1175.
20. Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141:2382-2391.
21. Håkansson I, Tisell A, Cassel P, et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J Neuroinflammation. 2018;15:209.
22. Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857-870.
23. Rejdak K, Kuhle J, Ruegg S, et al. Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury. Epilepsia. 2012;53:922-927.
24. Duncan JS. Seizure-induced neuronal injury: human data. Neurology. 2002;59:515-520.
25. Meldrum BS. Why and when are seizures bad for the brain? Trends Pharmacol Sci. 2001;22:445-446.
26. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015;84:1639-1643.
27. Siller N, Kuhle J, Muthuraman M, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scier. 2019;25:679-686.
28. Varhau KN, Torkildsen Ø, Myhr KM, et al. Neurofilament light chain as a biomarker in multiple sclerosis. Front Neurol. 2019;10:338.
29. Aronson JK, Ferner RE. Biomarkers—a general review. Curr Protoc Pharmacol. 2017;69:231-9.23.17.
30. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
31. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:566-580.
32. Wolff CA, Holmes SP, Young BD, et al. Magnetic resonance imaging for the differentiation of neoplastic, inflammatory, and cerebrovascular brain disease in dogs. J Vet Intern Med. 2012;26:589-597.
33. Comelis I, Volk HA, De Decker S. Clinical presentation, diagnostic findings and long-term survival in large breed dogs with meningoencephalitis of unknown origin. Vet J. 2019;254:105395.